AEMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aethlon Medical Inc (AEMD) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is experiencing significant financial challenges, a bearish technical setup, and lacks positive catalysts or strong institutional support. Additionally, there are no proprietary trading signals indicating a buy opportunity.
The stock is in a bearish trend with MACD below zero and negatively expanding, RSI at 18.608 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The current price of $1.95 is near the support level of $1.992, with further downside risk towards $1.823.
The company is progressing in its Australian oncology trial and collaborating with Stavro to evaluate the Hemopurifier's compatibility with blood treatment platforms.
The company reported a Q3 loss of -$2.45 per share, missed EPS estimates, and is facing liquidity pressures with only $7 million in cash reserves. Operating expenses increased by 13.6%, and the company has a history of beating EPS estimates only 50% of the time over the past two years.
In Q3 2026, the company reported zero revenue growth YoY, a net income loss of -$2,018,245 (up 15.01% YoY), and a significant drop in EPS to -2.45 (-75.62% YoY). Gross margin remains at 0%.
No recent analyst ratings or price target changes are available. The stock lacks strong Wall Street support or positive sentiment.
